Task B17: TB Therapeutic Manufacturing Request

任务 B17：结核病治疗药物生产请求

• 批准号: 10329717
• 负责人: BRUCE BLOUGH
• 金额: $ 1.67万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-06 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10329717
• 关键词: Chemistry; Communicable Diseases; Development; Development Plans; Drug Kinetics; Evaluation; In Vitro; Interventional Agent Development; Lead; Microbiology; Mycobacterium tuberculosis; Safety; Services; Support Contracts; Therapeutic; Toxicology; Toxin; in vivo; pathogen; pre-clinical; product development; programs; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

传染病介入性药物开发的非临床服务项目提供服务，以促进有前途的传染病病原体和/或毒素疗法的临床前产品开发。服务内容包括：临床前产品开发规划与评估；领导识别和开发；化学和GMP制造；体外和体内临床前微生物学，安全性，毒理学和药代动力学。